Karo Pharma intends to change listing venue to Nasdaq First North Growth Market during the first half of 2022
The board of directors of Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has resolved to initiate a process to have the Company’s shares listed on Nasdaq First North Growth Market and delisted from Nasdaq Stockholm (the “First North Listing”). The First North Listing is expected to be completed during the first half of 2022, in connection with the rights issue intended to repay the bridge loan facility provided to finance the acquisition of Sylphar International NV announced on 22 November 2021. Karo is on a journey to build a pan-European consumer healthcare company. The